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ABSTRACT 
 
 The sensitization of nociceptors generates injury-induced pain states and contributes to the 
development of chronic pain. Previous studies show that inhibiting mRNA translation through 
mechanistic target of rapamycin (mTOR) and mitogen activated protein kinase (MAPK) pathways 
blocks the development of nociceptor sensitization. These pathways signal convergently to the mRNA 
elongation initiation factor (eIF) 4F complex to regulate sensitization of nociceptors but the details of 
this process are obscure. Here we investigated the hypothesis that phosphorylation of the 5’ cap-
binding protein, eIF4E, by its specific kinase MAPK interacting kinase (MNK) 1/2 is a key factor in 
nociceptor sensitization and the transition to chronic pain using eIF4ES209A mice. Phosphorylation of 
ser209 on eIF4E regulates the translation of a subset of mRNAs. We show that pro-nociceptive and 
inflammatory factors, such as nerve growth factor (NGF), interleukin 6 (IL-6) and carrageenan, produce 
decreased mechanical and thermal hypersensitivity, decreased affective pain behaviors and strongly 
reduced hyperalgesic priming in the absence of eIF4E phosphorylation. Moreover, in patch clamp 
electrophysiology and Ca2+ imaging experiments on dorsal root ganglion (DRG) neurons, the effects of 
NGF and IL-6 on excitability measures are attenuated in neurons from eIF4ES209A mice. These effects 
were recapitulated in Mnk1/2-/- mice and with the MNK1/2 inhibitor, cercosporamide. We also find that 
cold hypersensitivity induced by peripheral nerve injury is reduced in eIF4ES209A and Mnk1/2-/- mice and 
by cercosporamide treatment. Our findings demonstrate that the MNK1/2 – eIF4E signaling axis is a 
major contributing factor to mechanisms of nociceptor plasticity and the transition to chronic pain. 
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SIGNIFICANCE STATEMENT  
 Chronic pain is a debilitating disease affecting approximately 1 in 3 Americans. Chronic pain is 
thought to be driven by changes in the excitability of peripheral nociceptive neurons but the precise 
mechanisms controlling these changes are not elucidated. Emerging evidence demonstrates that 
mRNA translation regulation pathways are key factors in changes in nociceptor excitability. Our work 
demonstrates that a single phosphorylation site on the 5’ cap-binding protein eIF4E is a critical 
mechanism for changes in nociceptor excitability that drive the development of chronic pain. We 
reveal a new mechanistic target for the transition to a chronic pain states and propose that targeting 
the upstream kinase, MNK1/2, could be used as a therapeutic approach for chronic pain.    
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INTRODUCTION 
 Translation of mRNAs is dynamically regulated in cells by upstream signaling factors that 
respond to a broad variety of receptors including ion channels, G-protein coupled receptors (GPCRs) 
and tyrosine receptor kinases (trks). For example, in DRG neurons nerve growth factor (NGF) and 
interleukin 6 (IL-6), two extracellular ligands intimately linked to pain across mammalian species, signal 
via their cognate receptors to the mTOR and MAPK pathways to induce eIF4F complex formation and 
promote translation (Melemedjian et al., 2010). The eIF4F complex is composed of the 5’ cap binding 
protein eIF4E, the deadbox RNA helicase eIF4A, and the scaffolding protein eIF4G. Phosphorylation 
of 4E-binding proteins (4E-BPs) by mTOR relieves inhibition on eIF4E and allows for eIF4E association 
with eIF4G and eIF4A to form the eIF4F complex, which promotes cap-dependent translation 
(Sonenberg and Hinnebusch, 2009). On the other hand, MAPKs act via the MAPK interacting kinases 
MNK1/2 to phosphorylate eIF4E at Serine 209 (Pyronnet et al., 1999; Waskiewicz et al., 1999). 
Interestingly, the precise role of eIF4E phosphorylation is not known but eIF4E phosphorylation has 
been linked to cellular plasticity in cancer (Furic et al., 2010) and immunity (Herdy et al., 2012). Its 
physiological role in the context of sensory neuron plasticity leading to pathological pain is unexplored.  
 The diversity of mechanisms of translation control by the eIF4F proteins is more complex than 
previously thought. It is now known that specific phosphorylation events on specific eIF4F complex 
proteins control the translation of specific subsets of mRNAs. The mTOR pathway has recently been 
shown to primarily influence the translation of mRNAs that contain terminal oligopyrimidine tracts in 
their 5’ untranslated regions (UTRs) (Thoreen et al., 2012). Similarly, the RNA helicase eIF4A primarily 
influences the translation of mRNAs with highly structured 5’ UTRs and/or 5’ UTRs that contain 
sequence motifs that form G quadruplexes (Wolfe et al., 2014). In the context of pain, two recent studies 
have shown distinct phenotypes in 4E-BP1 knockout mice or when eIF2 phosphorylation is genetically 
reduced. 4E-BP1 knockout mice show increased spinal cord expression of neuroligin 1 and enhanced 
mechanical sensitivity with no change in thermal thresholds (Khoutorsky et al., 2015). On the other 
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hand, mice lacking eIF2 phosphorylation on one allele have reduced responses to thermal stimulation 
and a deficit in thermal hypersensitivity after inflammation but normal mechanical pain (Khoutorsky et 
al., 2016). These studies highlight that distinct translation regulation signaling pathways produce 
diverse sensory phenotypes.  
 The goal of this study was to test the hypothesis that eIF4E phosphorylation is a central regulator 
of nociceptive plasticity and the transition to a chronic pain state. We tested this hypothesis using mice 
lacking the phosphorylation site for MNK1/2 on eIF4E (eIF4ES209A), mice lacking both Mnk1 and 2 (Mnk-
/-) (Ueda et al., 2004) and an inhibitor of MNK1/2 kinase activity, cercosporamide (Altman et al., 2013). 
We find that, different from 4E-BP1 knockouts or eIF2 mutants (Khoutorsky et al., 2015; Khoutorsky 
et al., 2016), eIF4E phosphorylation does not influence acute pain behavior but does promote 
nociceptor sensitization by a variety of endogenous factors known to promote pain in humans (NGF 
and IL-6) as well as exogenous pain-sensitizing factors. Moreover, eIF4E phosphorylation is a major 
contributor to the transition to a chronic pain state as shown in hyperalgesic priming, where mechanical 
hypersensitivity and grimacing is decreased and in neuropathic pain models where cold hypersensitivity 
is decreased. Our findings elucidate a new pathway regulating plasticity in the nociceptive system with 
implications for understanding signaling mechanisms in nociceptors that promote the transition to a 
chronic pain state. 
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MATERIALS and METHODS 
Experimental animals  
 Male and female eIF4ES209A mice on a C57BL/6 background were generated in the Sonenberg 
laboratory at McGill University, as described previously (Furic et al., 2010), and bred at The University 
of Arizona or The University of Texas at Dallas to generate experimental animals. Mnk1/2-/- mice on a 
C57BL/6 background were obtained from Rikiro Fukunaga (Ueda et al., 2004) and bred at McGill 
University. All animals were genotyped using DNA from ear clips taken at the time of weaning and all 
animals were backcrossed to C57Bl/6 background for at least 10 generations prior to experiments. All 
electrophysiological experiments using eIF4ES209A and WT mice were performed using mice between 
the ages of 4 and 6 weeks of age at the start of the experiment. Behavioral experiments using 
eIF4ES209A and WT mice were performed using mice between the ages of 8 and 12 weeks, weighing 
approximately 20 – 25 g. Experiments using ICR mice obtained from Harlan Laboratories (Houston, 
TX) were performed using mice between 4 to 8 weeks of age, weighing approximately 20 – 25 g at 
the start of the experiment.  All animal procedures were approved by Institutional Animal Care and 
Use Committees at The University of Arizona, The University of Texas at Dallas or McGill University 
and were in accordance with International Association for the Study of Pain guidelines. 
 
Antibodies and chemicals 
 The peripherin and neurofilament 200 (NF200) antibodies used for immunohistochemistry 
(IHC) were obtained from Sigma Aldrich (St. Louis, MO). Isolectin B4 (IB4) conjugated to Alexa-Fluor 
568 and secondary Alexa-Fluor antibodies were from Life Technologies (Grand Island, NY). 
Calcitonin gene-related peptide (CGRP) antibody was purchased from Peninsula Laboratories 
International, Inc. (San Carlos, CA). Transient receptor potential V1 (TRPV1) antibody was procured 
from Neuromics (Edina, MN). The phospho- and total- eIF4E, 4EBP1, ERK, and GAPDH antibodies 
were obtained from Cell Signaling Technology (Danvers, MA). The phospho- eIF4E antibody used for 
immunohistochemistry (IHC) was purchased from Abcam (Cambridge, UK). (RS)-3,5-
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Dihyroxyphenylglycin (DHPG) was purchased from Tocris Bioscience (Ellisville, MO). 
Cercosporamide was provided as a generous gift from Eli Lilly and Company (Indianapolis, IN) to the 
Sonenberg laboratory. Mouse nerve growth factor (NGF) was obtained from Millipore (Billierca, MA). 
Recombinant human or mouse interleukin-6 (IL-6) was purchased from R & D systems (Minneapolis, 
MN). 2-aminothiazol-4-yl-LIGRL-NH2 (2at-LIGRL) was synthesized in our laboratory as described 
previously (Boitano et al., 2011). Prostaglandin E2 (PGE2) was purchased from Cayman chemicals 
(Ann Arbor, MI). -cyclodextrin (45% weight/volume in H2O) was purchased from Sigma Aldrich (St. 
Louis, MO). All other chemicals were attained from ThermoFisher Scientific (Waltham, MA). See 
Table 1 for additional details on antibodies and chemicals used in this study. 
 
Behavior 
 Mice were housed on 12-hr light-/dark cycles with lights on at 7:00 AM. Mice had food and 
water available ad libitum. All behavioral experiments were performed between the hours of 9:00 AM 
and 4:00 PM. Mice were randomized to groups from multiple cages to avoid using mice from 
experimental groups that were cohabitating. Sample size was estimated by performing a power 
calculation using G*Power (version 3.1.9.2).  With 80% power, an expectation of d = 2.2 effect size in 
behavioral experiments, and alpha set to 0.05, the sample size required was calculated as n = 5 per 
group. We therefore sought to have an n = 6 in all behavioral experiments. Standard deviation (set at 
0.3) for the power calculation was based on previously published mechanical threshold data.  The 
actual number of animals used in each experiment was based on available animals of the appropriate 
sex and weight but was at least n = 5 for behavior experiments, with the exception of testing the 
effects cercosporamide on cold hypersensitivity after SNI where the sample size was determined by 
amount of available drug and dosing schedule given previous publications (see Table 2). Mice were 
habituated for 1 hr to clear acrylic behavioral chambers before beginning the experiment. Mechanical 
paw withdrawal thresholds were measured using the up-down method (Chaplan et al., 1994) with 
calibrated Von Frey filaments (Stoelting Company, Wood Dale, IL). Thermal latency was measured 
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using a Hargreaves device ((Hargreaves et al., 1988) IITC Life Science Inc.) with heated glass. 
Settings of 29°C glass, 20% active laser power, and 20 sec cut-off were used. Facial grimacing was 
evaluated using the Mouse Grimace Scale (MGS) as described previously (Langford et al., 2010). 
Nocifensive behavior in the formalin test was defined as licking, biting, or shaking of the affected paw, 
and was recorded over an observation period of 45 min. For intraplantar (i.pl.) injections, 50 ng NGF, 
0.1 ng IL-6, 10 or 20 ng 2at-LIGRL were diluted in 0.9% saline and injected with a volume of 25 μL via 
a 30 ½ -gauge needle. For intrathecal (i.t.) injections 50 nmol of DHPG were injected in a volume of 5 
μL via a 30 ½ -gauge needle (Hylden and Wilcox, 1980). Cercosporamide for local injection was 
made up in 10% DMSO and 45% -cyclodextrin in water and injected into the paw 15 min prior NGF, 
and simultaneously with 2at-LIGRL. Cercosporamide was injected i.t. in a volume of 5 L at the time 
of NGF i.pl. injection. Mice of both sexes were used in most experiments and no significant 
differences between sexes were noted for drug or genotype in any experiments. Sex of mice used in 
all behavioral experiments is shown in Table 2. The experimenter was blinded to the genotype of the 
mice and drug condition in all experiments. Behavioral experiments were performed by JKM, AK, 
MNA, PBI and SM. 
 
Immunohistochemistry (IHC)  
 Animals were anesthetized with isoflurane and euthanized by decapitation and tissues were 
flash frozen in O.C.T. on dry ice. Spinal cords were pressure ejected using chilled 1X phosphate 
buffered saline (PBS). Sections of spinal cord (25 μm), DRG (20 μm), and glaborous skin (25 μm) 
were mounted onto SuperFrost Plus slides (Thermo Fisher Scientific, Waltham, MA) and fixed in ice-
cold 10% or 4% (skin) formalin in 1X PBS for 1 or 4 hr (skin) then subsequently washed 3 times for 5 
min each in 1X PBS. Slides were then transferred to a solution for permeabilization made of 1X PBS 
with 0.2% Triton X-100 (Sigma Aldrich). After 30 min, slides were washed 3 times for 5 min each in 
1X PBS. Tissues were blocked for at least 2 hr in 1X PBS and 10% heat-inactivated normal goat 
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serum. Antibodies for CGRP, IB4, and TRPV1 were applied together and incubated with spinal cord 
and DRG sections on slides at 4° C overnight. A combination of TRPV1 and p-eIF4E antibodies were 
applied to glabrous skin sections and incubated at 4° C overnight. DRG slices were also stained with 
peripherin and NF200. Immunoreactivity was visualized following 1 hr incubation with goat anti-rabbit, 
goat anti-mouse, and goat anti-guinea pig Alexa-Fluor antibodies at room temperature. All IHC 
images are representations of samples taken from 3 animals per genotype except for glaborous skin 
IHC where 2 animals per genotype were used. Images were taken using an Olympus FluoView 1200 
confocal microscope. Analysis of images was done using ImageJ Version 1.48 for Apple OSX 
(National Institutes of Health, Bethesda, MD). 
 
Western blotting 
 Male mice were used for all Western blotting experiments and were sacrificed by decapitation 
following anesthesia and tissues were flash frozen on dry ice. Frozen tissues were homogenized in 
lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA pH 8.0, and 1% Triton X-100) containing 
protease and phosphatase inhibitors (Sigma Aldrich), and homogenized using a pestle. In vitro 
studies testing the effects of cercosporamide (Figure 6A) consisted of cultured primary DRG neurons 
from ~ 20 g mice. Mice were anesthetized with isoflurane and euthanized by decapitation. DRGs 
were dissected and placed in chilled Hank’s Balanced Salt Solution (HBSS, Invitrogen) until 
processed. DRGs were then digested in 1 mg/mL collagenase A (Roche) for 25 min at 37 °C then 
subsequently digested in a 1:1 mixture of 1 mg/mL collagenase D and papain (Roche) for 20 min at 
37 °C. DRGs were then triturated in a 1:1 mixture of 1 mg/mL trypsin inhibitor (Roche) and bovine 
serum albumin (BioPharm Laboratories, LLC), then filtered through a 70 μm cell strainer (Corning). 
Cells were pelleted then resuspended in Dulbecco’s Modified Eagle’s Medium (DMEM) / F12 + 
Glutamax (Life Technologies) containing 10% fetal bovine serum (FBS, Life Technologies), 1% 
penicillin and streptomycin, and 3 μg/ml 5-fluorouridine with 7 μg/ml uridine to inhibit mitosis of non-
neuronal cells and distributed evenly in a 6-well plate coated with poly-D lysine (Becton Dickenson 
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[BD]). DRG neurons were maintained in a 37°C incubator containing 5% CO2 with a media change 
every other day. On day 5, DRG neurons were treated as indicated in the results section, and cells 
were rinsed with chilled 1X PBS and harvested in lysis buffer containing protease and phosphatase 
inhibitors (Sigma-Aldrich), and then sonicated for 10 sec. To clear debris, samples were centrifuged 
at 14,000 rpm for 15 min at 4°C. Ten to 15 g of protein was loaded into each well and separated by 
a 10% SDS-PAGE gel. Proteins were transferred to a 0.45 PVDF membrane (Millipore, Billierca, MA) 
at 30V overnight at 4 °C. Subsequently, membranes were blocked with 5% non-fat dry milk (NFDM) 
in 1X Tris buffer solution containing Tween 20 (TTBS) for 3 hr. Membranes were washed in 1X TTBS 
3 times for 5 min each, then incubated with primary antibody overnight at 4 °C. The following day, 
membranes were washed 3 times in 1X TTBS for 5 min each, then incubated with the corresponding 
secondary antibody at room temperature for 30 min to 1 hr. Membranes were then washed with 1X 
TTBS 6 times for 5 min each. Signals were detected using Immobilon Western Chemiluminescent 
HRP substrate (Millipore). Bands were visualized using film (Kodak; Rochester, NY) or with a Bio-Rad 
(Hercules, CA) ChemiDoc Touch. Over-exposed or saturated pixels detected by the ChemiDoc Touch 
were not used in analysis. Membranes were stripped using Restore Western Blot Stripping buffer 
(Thermo Fisher Scientific), and re-probed with another antibody. Analysis was performed using 
ImageJ v1.48 (NIH).  
 
Ca2+ Imaging 
WT and eIF4ES209A DRG neurons were dissociated and cultured as described above with the 
exception that cells were plated on glass-bottom poly-D-lysine coated dishes (MatTEK Incorporation). 
DRG neurons were maintained in a 37°C incubator containing 5% CO2 with no media changes. 
 Ca2+ imaging experiments began 48 hr after dissociation. Each dish was loaded with 10 μg/mL 
of fura-2 AM (Life Technologies) along with IL-6 (50ng/mL) or vehicle in Hank’s Buffered Salt Solution 
(HBSS, Invitrogen) supplemented with 0.25% w/v bovine serum albumin and 2 mM CaCl2, for 1 hr at 
37°C. The cells were then changed to bath solution (125 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 M 
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CaCl2, 1 M MgCl2, and 2 M glucose pH 7.4 adjusted with N-methyl Glucamine and ~ 300 mosM) for 30 
min in a volume of 2 mL for esterification. Dishes were then washed with 2 mL of bath solution prior to 
recordings. Only neurons were used in the analysis and these were defined as cells with 10% or higher 
ratiometric change in intracellular Ca2+ in response to the 50 mM KCl perfusion. Maximum Ca2+ release 
was calculated by comparing ratio value change by time compared to baseline. A change of at least 
10% intracellular Ca2+ in response to 1 nM PGE2 or 250 nM capsaicin was used to classify as neuron 
as responsive to the stimulus. Experiments were conducted using the MetaFluor Fluorescence Ratio 
Imaging Software on an Olympus TH4-100 apparatus (Olympus).  
 
Extracellular electrophysiology 
 
MEA-based extracellular recording experiments were performed on dissociated mouse DRG 
neurons between day-in-vitro 11 and 15 using Ti or ITO 60-channel planar microelectrode arrays 
(Multichannel Systems, Reutlingen, Germany) equipped with hardware/software from Plexon, Inc. 
Data were acquired at 40 kHz/channel and digitally filtered (0.1 to 7000 Hz bandpass) during 
acquisition. An additional 4-pole Butterworth bandpass filter (250 Hz to 7500 Hz) was applied to raw, 
continuous data, enabling detection of single-event extracellular voltage changes (spikes). Spikes 
were defined by filtered data crossing a 5σ threshold based on root mean square values calculated 
for each channel. Active channels were defined by template spike detection resulting in average 
waveform amplitudes of 40 μV or higher during any of the three 1 hour experimental intervals: 
baseline, IL-6 treatment, and wash. Between each interval, recording was paused for ~ 2 min to allow 
for manual exchange of culture medium for medium + IL-6 (IL-6 treatment, 50 ng/mL) or fresh culture 
medium (Wash). Active channel data was exported to NeuroExplorer (Nex Technologies, Madison, 
AL) for mean spike rate calculations and further analysis. Statistical comparisons of channel activity 
were carried out using OriginPro software (OriginLab, Northhampton, MA). MEA cultures were 
maintained at 37 ˚C, 5% CO2, and 90% humidity throughout all experiments (OKO Labs, Pozzuoli, 
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Italy). Culture-surface preparation, DRG extraction, dissociation, and cell seeding was carried out as 
described above. 
 
Patch-clamp Electrophysiology 
 For culturing DRGs, acutely dissected DRGs were incubated for 15 min in 20 units/ml Papain 
(Worthington) followed by 15 min in 3 mg/ml Collagenase Type II (Worthington). After trituration 
through a fire-polished Pasteur pipette, dissociated cells were resuspended in Liebovitz L-15 medium 
(Life Technologies) supplemented with 10% fetal bovine serum (FBS), 10 mM glucose, 10 mM 
HEPES and 50 units/ml penicillin/streptomycin and plated on poly-D-lysine and laminin (Sigma) - 
coated dishes. Cells were allowed to adhere for several hours at room temperature in a humidified 
chamber and covered with media described above.  DRG neurons were treated with 50 ng/ml NGF 
18 – 24 hr prior to recordings or with 50ng/ml mouse IL-6 for 1 hr. 
 Whole cell patch-clamp experiments were performed on isolated mouse DRG neurons within 
24 hr of dissociation using a MultiClamp 700B (Axon Instruments, Sunnyvale, CA) patch-clamp 
amplifier and PClamp 9 acquisition software (Axon Instruments). Recordings were sampled at 2 kHz 
and filtered at 1 kHz (Digidata 1322A, Axon Instruments). Pipettes (OD: 1.5mm, ID: 0.86mm) were 
pulled using a P-97 puller (Sutter Instrument, Novato, CA) and heat polished to 1.5-4 MΩ resistance 
using a microforge (MF-83, Narishige, East Meadow, NY). Series resistance was typically <7 MΩ and 
was compensated 60-80%. Data were analyzed using Clampfit 10 (Molecular Devices, Sunnyvale, 
CA) and Origin 8 (OriginLab, Northhampton, MA). All neurons included in the analysis had a resting 
membrane potential (RMP) -60 mV or lower. The RMP was recorded 1–3 min after achieving whole-
cell configuration. In current-clamp mode, action potentials were elicited by injecting slow ramp 
currents from 0.1 to 0.7 nA with Δ = 0.2 nA over 1 s to mimic slow depolarization. The pipette solution 
contained (in mM) 140 KCl, 11 EGTA, 2 MgCl2, 10 NaCl, 10 HEPES, 1 CaCl2 pH 7.3 (adjusted with 
N-methyl glucamine), and was ~ 320 mosM. External solution contained (in mM) 135 NaCl, 2 CaCl2, 
1 MgCl2, 5 KCl, 10 Glucose, 10 HEPES, pH 7.4 (adjusted with N-methyl glucamine), and was ~ 320 
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mosM. For neuronal VGNaC current recordings, pipette solution contained (in mM) 120 CsCl, 10 
EGTA, 2 MgCl2, 5 NaCl, 10 HEPES, 2 CaCl2, pH 7.3 (adjusted with N-methyl glucamine) and 
osmolarity was 320 mosM. External solution contained (in mM) 95 Choline, 20 Tetraethyl ammonium 
(TEA), 20 NaCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 5 KCl, 0.1 CdCl2, 0.1 NiCl2, pH 7.3 (adjusted with N-
methyl glucamine) and osmolarity was 320 mosM. In whole-cell configuration, cells were voltage-
clamped and VGNaC currents were evoked by a 50 ms depolarizing steps (from -80 to +40 mV in 5 
mV increments) from a holding potential of -120mV.  Sodium currents were normalized to whole-cell 
capacitance and expressed as current density (pA/pF). 
 
Statistics 
 All data are represented as mean ± standard error of the mean (SEM). Individual data points 
are represented in each graph to show the n in each group and the overall distribution of individual 
data points. All analysis was done using GraphPad Prism 6 v 6.0 for Mac OS X. Single comparisons 
were performed using Student’s t-test and multiple comparisons were performed using a two-way 
ANOVA with Bonferroni posthoc tests for across group comparisons or Uncorrected Fisher’s LSD for 
within group comparisons. Raw data from all experiments, including all of the statistical analysis, is 
available in prism file format as extended data. 
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RESULTS 
 Nociceptive reflexes, acute pain behavior and development of DRG to spinal dorsal horn 
connectivity is normal in eIF4ES209A mice 
 To test the hypothesis that eIF4E phosphorylation is a key factor in pain sensitization and the 
transition to a chronic pain state we used mice harboring a point mutation on the only known 
phosphorylation site in the eIF4E protein, S209 (Furic et al., 2010; Herdy et al., 2012; Gkogkas et al., 
2014). We compared baseline thermal (Figure 1A) and mechanical thresholds (Figure 1B) between 
eIF4ES209A mice and their wildtype (WT) littermates and noted no differences in tail flick latencies to 
55C water or von Frey stimulation. When 5% formalin, a commonly used noxious irritant, was injected 
into the hindpaw no differences in pain behaviors were noted between genotypes in either the first 
(Figure 1C, 0 – 10 min) or second (Figure 1D, 15 – 45 min) phases of the test. However, when 
mechanical sensitivity was examined 3 days after formalin administration there was a striking difference 
between genotypes, with eIF4ES209A mice failing to develop mechanical hypersensitivity. The group I 
metabotropic glutamate receptor (mGluR) agonist, dihydroyphenylglycine (DHPG), promotes tonic 
pain-related behaviors when injected intrathecally (Karim et al., 2001). These behaviors are decreased 
by inhibition of spinal mTOR signaling (Price et al., 2007). We did not detect any difference in acute 
pain behaviors upon DHPG intrathecal (i.t.) injection between genotypes (Figure 1F), but 6 hr following 
injection eIF4ES209A mice again showed a reduction in the magnitude of mechanical hypersensitivity 
(Figure 1G). 
 We next used a variety of histochemical markers to assess the possibility of developmental 
differences in sensory anatomy between eIF4ES209A mice and WT littermates. In both WT (Figure 2A) 
and eIF4ES209A (Figure 2B) mice there was a clear delineation between the projections of calcitonin 
gene-related peptide (CGRP) positive afferents and the isolectin B4 (IB4) population to lamina II of the 
dorsal horn. This was also true for TRPV1-positive and IB4-positive staining while CGRP and TRPV1 
afferents overlapped heavily in projections to lamina I and lamina II. Peripherin is expressed 
predominately in unmyelinated neurons in the DRG, whereas NF200 staining is used to label 
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myelinated, large diameter afferents that are mostly A fibers. These two populations were non-
overlapping in both genotypes (Figure 2C) and the proportions of DRG neurons expressing these 
markers were equivalent (Figure 2C). Neuronal populations expressing TRPV1, IB4, and CGRP were 
also no different in eIF4ES209A versus WT DRGs (Figure 2D). 
 We were concerned about the possibility of feedback signaling that might change activity in 
upstream signaling pathways (Carracedo et al., 2008; Melemedjian et al., 2013) and complicate 
interpretation of experimental results. We dissected lumbar DRG and dorsal horn of the spinal cord 
from WT and eIF4ES209A mice and examined eIF4E, extracellular signal regulated protein kinase (ERK) 
and 4E-BP phosphorylation in both tissues by Western blot. While eIF4E phosphorylation was 
completely absent in eIF4ES209A mice, there was no change in either ERK (Figure 3A) or 4E-BP (Figure 
3B) phosphorylation in DRG or spinal cord (Figure 3C and D) in eIF4ES209A mice. These results rule out 
the possibility of feedback signaling in the ERK and mTOR pathways in tissues relevant to algesiometric 
assays. 
 Deficits in mechanical sensitization, affective pain expression, and the development of 
hyperalgesic priming in eIF4ES209A mice 
Previous studies have shown that IL-6, NGF (Melemedjian et al., 2010) and activation of 
protease activated receptor 2 (PAR2) (Tillu et al., 2015) promote mechanical hypersensitivity in an 
ERK-dependent fashion that requires de novo, local protein synthesis. To test the role of eIF4E 
phosphorylation in this process we injected IL-6, NGF and the PAR2 agonist, 2at-LIGRL (Flynn et al., 
2011) into the hindpaw of WT and eIF4ES209A mice. IL-6 (0.1 ng) injected into the paw evoked 
mechanical hypersensitivity lasting approximately 72 hr (Figure 4A) in WT mice. The magnitude of 
mechanical hypersensitivity was significantly reduced in eIF4ES209A mice 24, 48 and 72 hr after injection 
(Figure 4A). We, and others, have previously shown that activity-dependent translation regulation 
pathways are required for the full expression of hyperalgesic priming (Melemedjian et al., 2010; Asiedu 
et al., 2011; Bogen et al., 2012; Melemedjian et al., 2014; Ferrari et al., 2015a; Ferrari et al., 2015b) 
but the role of eIF4E phosphorylation in this transition to a chronic pain state has not been addressed. 
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We “primed” WT and eIF4ES209A mice with IL-6 (Figure 4A) and, after their mechanical thresholds had 
completely returned to baseline, challenged these mice with a dose of PGE2 (100 ng) that fails to induce 
mechanical hypersensitivity in “unprimed” mice. We observed that the response to PGE2 injection in 
eIF4ES209A mice was blunted compared to WT mice (Figure 4B). 
Similar experiments were done using a hindpaw injection of NGF (50 ng). NGF evoked robust 
mechanical hypersensitivity in WT mice, whereas in eIF4ES209A mice it was dramatically reduced 
(Figure 5C). After the mice returned to baseline mechanical thresholds, we assessed priming with a 
hindpaw injection of PGE2. We observed that similar to IL-6-induced priming, NGF was unable to 
produce the same magnitude of priming in eIF4ES209A mice compared to WT mice (Figure 4D). To 
examine whether changes in thermal hypersensitivity were also present in these mice we used the 
Hargreaves test (Hargreaves et al., 1988) in mice treated with NGF.  We observed decreased thermal 
hyperalgesia in eIF4ES209A mice compared to WT (Figure 4E) and a transient thermal hypersensitivity 
during priming in WT mice, but no change in eIF4ES209A mice (Figure 4F). 
Likewise, the specific PAR2 agonist 2at-LIGRL (20 ng) evoked mechanical hypersensitivity and 
hyperalgesic priming precipitated by PGE2 in WT mice but this effect was strongly reduced in eIF4ES209A 
mice (Figure 4G and H). These results indicate that eIF4E phosphorylation is a key downstream event 
for pronociceptive factors that act via the ERK pathway to promote mechanical and thermal 
hypersensitivity, but whether this also influences spontaneous, non-evoked components of pain is not 
known. We used the mouse grimace scale (MGS) (Langford et al., 2010) to determine this with hindpaw 
injection of 2at-LIGRL (20 ng). While PAR2 activation induced a robust grimacing in WT mice, this 
effect was reduced in eIF4ES209A mice (Figure 4I) suggesting that this signaling pathway is critical for 
full expression of affective pain components downstream of ERK activation. Additionally, when we 
measured facial grimacing in response to PGE2 injection in mice previously injected with 2at-LIGRL, 
there was a significant increase in grimacing in WT mice but no change in facial expression scores in 
eIF4ES209A mice (Figure 4J). 
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 Mechanical and thermal hypersensitivity induced by complex inflammatory stimuli are regulated 
by MNK1/2- eIF4E phosphorylation signaling 
 While the findings above indicate that eIF4E phosphorylation strongly contributes to mechanical 
and thermal hypersensitivity induced by algogens that signal via ERK, we asked if eIF4E 
phosphorylation likewise play an important role in mechanical and thermal hypersensitivity induced by 
inflammation. We utilized a hindpaw injection of carrageenan (0.5% w/v) in WT and eIF4ES209A mice 
and measured mechanical (Figure 5A) and thermal hypersensitivity (Figure 5B). WT mice developed 
robust mechanical and thermal hypersensitivity whereas this effect was abrogated in eIF4ES209A mice 
(Figure 5A and B). When we tested if carrageenan-induced hyperalgesic priming was dependent on 
eIF4E phosphorylation, we observed that WT mice developed increased long-lasting mechanical 
hypersensitivity compared to eIF4ES209A mice when priming was precipitated with PGE2 injection 
(Figure 5C).  
 Additionally, we utilized mice lacking MNK1 and 2 (MNK-/- mice) and complete Freund’s adjuvant 
(CFA) to further test the role of this signaling axis in inflammatory pain. We injected CFA (0.5 mg/mL in 
10μL) into the hindpaw of WT and MNK-/- mice. While we observed mechanical (Figure 5D) and thermal 
(Figure 5E) hypersensitivity in both WT and MNK-/- mice at early time points, MNK-/- mice recovered 
faster than their WT littermates. When we tested if MNK-/- mice transitioned into the “primed” state with 
a subsequent injection of PGE2, we saw reduced mechanical (Figure 5F) and thermal (Figure 5G) 
hypersensitivity in MNK-/- mice but a robust response in WT mice.  
Pharmacological inhibition of MNK1/2 with cercosporamide recapitulates eIF4ES209A phenotypes 
To determine whether cercosporamide inhibits eIF4E phosphorylation in DRG neurons these 
cells were cultured for 5 days and exposed to 10 M cercosporamide (Altman et al., 2013) or vehicle 
for 1 hr. Western blot analysis demonstrated a significant decrease of p-eIF4E in treated DRG neurons 
compared to vehicle (Figure 6A). Cercosporamide-treated DRG neurons showed no change in levels 
of p-4E-BP1 (Figure 6B), indicating that cercosporamide does not induce feedback activation of 
mTORC1. Levels of p-ERK were also unchanged (Figure 6C), demonstrating that upstream regulators 
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of MNK1/2 are unaffected by cercosporamide, and are not activated via a feedback mechanism as we 
have shown previously for mTORC1 inhibitors (Melemedjian et al., 2013). We also assessed whether 
systemic injection of cercosporamide (40 mg/kg) (Gkogkas et al., 2014)) in mice influenced eIF4E 
phosphorylation. In DRG tissue taken 2 hr after cercosporamide injection we observed a ~50% 
decrease in eIF4E phosphorylation (Figure 6D), whereas no effect was observed in 4E-BP1 
phosphorylation (Figure 6E).  
We then determined the effects of cercosporamide on NGF- and PAR2 activation-induced 
mechanical hypersensitivity and hyperalgesic priming in vivo. Similar to observations in eIF4ES209A 
mice, treatment with cercosporamide (10 g, intraplantar) 15 min prior to NGF (Figure 6F) produced 
blunted mechanical hypersensitivity acutely. Similar results were obtained when 2at-LIGRL was applied 
in the presence or absence of cercosporamide (Figure 6G).  When animals treated with NGF or 2at-
LIGRL were subsequently tested for hyperalgesic priming with PGE2 (Figure 6H and I) there was also 
a reduction in the magnitude of mechanical hypersensitivity. Moreover, co-injection of cercosporamide 
with 2at-LIGRL attenuated grimacing recorded 3 hr after injection (Figure 6J), and prevented facial 
grimacing (Figure 6K) in response to PGE2 injection, again consistent with observations in eIF4ES209A 
mice.  
Our demonstration that hindpaw cercosporamide administration reduces behavioral pain 
plasticity suggests that p-eIF4E-mediated local translation in peripheral nociceptive fibers contributes 
to this effect. We therefore sought to evaluate whether p-eIF4E could be observed in nerve fibers 
innervating the hindpaw. Glabrous skin from both WT and eIF4ES209A mice was immunostained for 
TRPV1 and p-eIF4E and imaged. We observed p-eIF4E in TRPV1 positive nerve fibers in WT mice 
and this staining was completely absent in eIF4ES209A mouse skin samples (Figure 6L) demonstrating 
the specificity of this antibody and the presence of p-eIF4E in terminals of TRPV1-positive nociceptors. 
eIF4E phosphorylation regulates DRG neuron excitability following NGF and IL-6 exposure  
To directly test the effect of NGF and IL-6 on DRG neuron excitability in the presence and 
absence of eIF4E phosphorylation we used patch clamp electrophysiology. DRG neurons were isolated 
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from WT and eIF4ES209A mice and exposed to 50 ng/mL NGF or vehicle for 18 – 24 hr prior to 
recordings. In WT neurons, NGF caused an increase in the number of action potentials fired in response 
to slowly depolarizing ramp currents of 100 through 700 pA amplitudes (Figure 7A). In contrast, DRG 
neurons isolated from eIF4ES209A mice showed elevated baseline excitability versus WT neurons but 
did not show a change in their excitability after exposure to the same concentration of NGF over an 
identical time course (Figure 7B). For the DRG neurons sampled from both treatments and genotypes 
there were no differences in membrane capacitance (Figure 7C) or other parameters such as resting 
membrane potential (WT:  -63.34 ± 1.12 mV, n=10; eIF4ES209A:  -61.63 ± 1.13 mV, n =11, p < 0.05, t-
test). We next examined NGF-induced changes in DRG excitability in the presence of cercosporamide 
(10 M) for 1 hr prior to recordings. Analogous to eIF4ES209A DRG neurons, cercosporamide inhibited 
NGF-induced hyperexcitability (Figure 7D), demonstrating that brief pharmacological inhibition of 
MNK1/2 reverses augmented excitability in DRG neurons induced by NGF treatment. 
Similar experiments were conducted with IL-6 (50 ng/mL), except that IL-6 was only applied for 
1 hr prior to patch clamp recordings. IL-6, as we have observed previously in rat trigeminal ganglion 
neurons (Yan et al., 2012), caused an increase in the number of action potentials fired in response to 
ramp current injection at 300, 500 and 700 pA amplitudes (Figure 7E). As we observed with NGF, IL-6 
failed to increase the excitability of DRG neurons from eIF4ES209A mice (Figure 7F). Again, there were 
no significant differences in membrane capacitance in the populations sampled for any of these 
experimental conditions (Figure 7G). When we examined the effect of cercosporamide on IL-6-induced 
hyperexcitability, we found that synonymous to eIF4ES209A DRG neurons, cercosporamide inhibited 
increased neuronal excitability induced by IL-6 treatment (Figure 7H).  
To assess if cercosporamide is specific to MNK1/2 in our behavioral paradigm, we utilized 
cercosporamide in eIF4ES209A mice and measured mechanical hypersensitivity induced by NGF. We 
found no differences in NGF-induced mechanical hypersensitivity between cercosporamide and vehicle 
injected eIF4ES209A mice (Figure 8A). Subsequent injection of PGE2 to precipitate hyperalgesic priming, 
additionally showed no difference in either eIF4ES209A mice previously injected with cercosporamide or 
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vehicle (Figure 8B). While these behavioral results suggest that cercosporamide’s actions are specific 
to MNK1/2, we also tested for a possible acute effect of cercosporamide on voltage-gated sodium 
channels (VGNaC) that could lead to a decrease in excitability and confound results with this drug. 
VGNaC currents were elicited in cultured DRG neurons by 50 msec depolarizing steps and currents 
were expressed as current density. Acute application of cercosporamide (10M) had no effect on 
VGNaC density ruling out this possibility (Figure 8C and D).  
As an independent assay to support our whole cell patch clamp electrophysiological findings, 
we assessed excitability with extracellular recordings using microelectrode arrays (MEAs). DRG 
neurons from both WT and eIF4ES209A mice were dissociated and cultured on MEA devices 
(Breckenridge et al., 1995; Potter and DeMarse, 2001; Frega et al., 2012; Enright et al., 2016) (Figure 
9A) for 11 – 15 days prior to recordings. Action potentials were recorded for 1 hr prior to IL-6 exposure, 
during 1 hr of IL-6 (50ng/mL) treatment, and again during a 1 hr washout period. WT and eIF4ES209A 
neurons were mostly silent during recordings preceding IL-6 exposure. In WT DRG neurons, spiking 
was significantly increased during IL-6 treatment and was maintained during washout (Figure 9B). In 
contrast, DRG neurons isolated from eIF4ES209A mice, showed a brief increase in spiking in response 
to IL-6 that rapidly decreased to spiking rates that were significantly less than what was observed in 
WT neurons (Figure 9C). 
The whole cell patch clamp and MEA experiments described above indicate that NGF and IL-6 
increase excitability in WT neurons but this response is blunted in eIF4ES209A DRG neurons. To further 
investigate the cellular mechanisms responsible for this effect, we examined the effect of IL-6 treatment 
on sodium current density. In DRG neurons from WT, there was a significant increase in sodium current 
density after 1 hr IL-6 treatment compared to vehicle suggesting that IL-6 treatment altered the number 
of available VGNaCs or changed channel gating properties in WT DRG neurons (Figure 9D). Consistent 
with voltage ramp experiments, baseline VGNaC density was higher in eIF4ES209A neurons. However, 
these neurons failed to respond to IL-6 with an increase in VGNaC density (Figure 9E). In fact, we 
observed a trend toward decreased VGNaC density in eIF4ES209A mice. From these experiments we 
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conclude that while baseline excitability and VGNaC availability may be higher in eIF4ES209A 
nociceptors, these neurons fail to respond to algogens with an increase in VGNaC-mediated 
responses. Importantly, this baseline increased VGNaC availability in eIF4ES209A DRG neurons does 
not lead to ectopic activity since no difference in spiking was observed at baseline in our MEA 
experiments (Figure 9B and C) and it does not seem to be recapitulated by brief cercosporamide 
treatment because we did not observe enhanced excitability in whole cell patch clamp experiments with 
this drug (Figure 8C and D).     
eIF4E phosphorylation regulates IL-6-induced enhancements in Ca2+ signaling in DRG neurons 
 To further elucidate the role of eIF4E phosphorylation on DRG excitability, we investigated IL-6-
induced changes in Ca2+ signaling in DRG neurons by measuring intracellular Ca2+ concentration [Ca2+]i 
with ratiometric imaging. Dissociated DRG neurons from both WT (Figure 10A) and eIF4ES209A (Figure 
10B) mice were loaded with fura-2 and treated with either vehicle or IL-6 (50 ng/mL) for 1 hr. Kinetic 
changes in [Ca2+]i in response to PGE2 (1 nM) were measured in all conditions. WT DRG neurons 
treated with IL-6 displayed a significant decrease in the latency to peak [Ca2+]i in response to PGE2 
compared to vehicle-treated neurons (Figure 10C). In contrast, DRG neurons isolated from eIF4ES209A 
mice showed no differences in the kinetics of PGE2-induced responses between IL-6 and vehicle 
treatments (Figure 10C). On the other hand, the number of WT DRG neurons responding with a [Ca2+]i 
rise above a threshold of 10% was drastically increased after IL-6 treatment whereas no change was 
observed in eIF4ES209A DRG neurons (Figure 10D). Capsaicin-evoked changes in [Ca2+]i were 
equivalent in both WT and eIF4ES209A DRG neurons (Figure 11A) and the proportion of TRPV1-positive 
DRG neurons (defined as those neurons responding to the specific agonist capsaicin) was the same in 
all conditions (Figure 11B), consistent with our immunostaining results. Responses in [Ca2+]i evoked by 
increasing extracellular K+ from 5 mM to 50 mM were also not different between genotypes (Figure 
11C).  
Cold hypersensitivity after peripheral nerve injury is reduced in eIF4ES209A and Mnk-/- mice  
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WT, Mnk-/- and eIF4ES209A mice were subjected to spared nerve injury (SNI) surgery and 
mechanical and cold hypersensitivity were measured over the ensuing 35 days. We observed a delay 
in the development of full mechanical hypersensitivity in eIF4ES209A mice but by 14 days these mice 
developed similar mechanical hypersensitivity to their WT littermates (Figure 12A). On the other hand, 
in Mnk-/- mice mechanical hypersensitivity after SNI was blunted in magnitude compared to WT mice 
(Figure 12B). eIF4ES209A mice displayed significantly less cold hypersensitivity than WT littermates 
throughout the time course of the experiment (Figure 12C), an effect that was also observed in Mnk-/- 
mice (Figure 12D). Finally, we asked if pharmacological inhibition of MNK1/2 with cercosporamide 
could alleviate cold hypersensitivity in SNI mice. We waited until 4 weeks after SNI (28 days) when 
mice display very stable cold hypersensitivity and treated mice with vehicle or 40 mg/kg cercosporamide 
for 3 consecutive days. On the third day we measured cold sensitivity using the acetone test. We 
observed decreased cold hypersensitivity in the cercosporamide-treated group at 1 hr after the third 
injection of drug (Figure 12E), suggesting that even late after the development of neuropathic pain 
targeting MNK1/2 signaling to eIF4E is able to alleviate some aspects of neuropathic pain. 
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DISCUSSION 
 The activity-dependent regulation of protein synthesis is a core mechanism mediating neuronal 
plasticity (Costa-Mattioli et al., 2009). In the nociceptive system, translation regulation pathways have 
been shown to contribute to the development and maintenance of pain hypersensitivity in a variety of 
preclinical models, suggesting that targeting these pathways may lead to new pain therapeutics (Price 
and Geranton, 2009; Obara et al., 2012; Melemedjian and Khoutorsky, 2015; Price and Inyang, 2015). 
Here we report that phosphorylation of eIF4E at S209 is a key biochemical event for the sensitization 
of DRG neurons by pro-nociceptive factors that are known to promote pain in rodents and humans, and 
that loss of this phosphorylation event does not affect baseline pain behaviors or neurodevelopment in 
the nociceptive system. Our electrophysiological and Ca2+ imaging experiments show that the 
generation of nociceptor hyperexcitability is influenced by eIF4E phosphorylation by MNK1/2. 
Moreover, eIF4E phosphorylation plays a key role in the transition to a chronic pain state as reflected 
by deficiencies in peripherally-mediated hyperalgesic priming and a loss of cold hypersensitivity after 
peripheral nerve injury. Our genetic and pharmacological experiments demonstrate that targeting 
MNK1/2 recapitulates the phenotype of eIF4ES209A mice pointing out that MNK1/2 might be 
advantageously targeted in the peripheral nervous system for the treatment and/or prevention of 
chronic pain conditions. 
 While upstream signaling factors like mTOR and MAPK have been implicated in pain plasticity 
using pharmacological tools and biochemical measures (Aley et al., 2001; Zhuang et al., 2004; Price 
et al., 2007; Jimenez-Diaz et al., 2008; Asante et al., 2009; Codeluppi et al., 2009; Geranton et al., 
2009; Asante et al., 2010; Melemedjian et al., 2010; Melemedjian et al., 2011; Obara et al., 2011; Ferrari 
et al., 2013; Melemedjian et al., 2014), specific downstream mechanisms and mRNA targets linked to 
these kinase signaling cascades have been elusive until very recently. Recent evidence suggests that 
different translation regulation targets play strikingly uniquely roles in different aspects of pain 
sensitivity. For example, genetic loss of a major downstream target of mTORC1, 4E-BP1, leads solely 
to changes in mechanical sensitivity via central mechanisms governed by a synaptic adhesion molecule 
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known as neuroligin 1 (Khoutorsky et al., 2015). In contrast, mice lacking a key phosphorylation site for 
eIF2 on a single allele have deficits in baseline thermal nociception without any changes in mechanical 
thresholds (Khoutorsky et al., 2016). This phenotype can be recapitulated with pharmacological 
modulation of eIF2 and a deficit in thermal, but not mechanical, hyperalgesia is also associated with 
this pathway in inflammatory pain. Collectively, these studies suggest that individual translation 
regulation pathways may target specific subsets of genes that have profound impacts on certain 
aspects of nociception (e.g. thermal versus mechanical pain; see Table 3 for a summary of previous 
findings compared to the present paper). We previously showed that NGF and IL-6 are capable of 
promoting eIF4E phosphorylation in nociceptors in vitro, and that disrupting eIF4F complex formation 
with 4EGI-1 leads to a blockade of the development of mechanical hypersensitivity and hyperalgesic 
priming by these pro-nociceptive factors (Melemedjian et al., 2010; Tillu et al., 2015). Here we used 
eIF4ES209A and MNK-/- mice and pharmacological tools to definitively demonstrate that eIF4E 
phosphorylation is a core biochemical event modulating how inflammatory stimuli promote mechanical 
and thermal hypersensitivity, spontaneous pain responses, and the transition to a chronic pain state. 
These findings distinguish the MNK1/2 – eIF4E signaling cascade from 4E-BP1 and eIF2 signaling 
which have specific effects on certain pain modalities. Our results support the conclusion that MNK1/2 
– eIF4E signaling plays an important role in altering the excitability of a wide population of nociceptors 
because genetic and pharmacological manipulation of this pathway had robust effects on thermal and 
mechanical hypersensitivity, as well as spontaneous pain. In our view, this identifies MNK1/2-mediated 
eIF4E phosphorylation as a crucial target for plasticity in nociceptors that drives the transition to a 
chronic pain state. MNK1/2-dependent signaling to eIF4E therefore represents a strong mechanistic 
target for pharmacological manipulation of chronic pain.  
Cold hypersensitivity induced by peripheral nerve injury was decreased in eIF4ES209A mice, but 
mechanical hypersensitivity developed normally, albeit with a delay to reach its full magnitude. This is 
in contrast to a clear deficit in mechanical hypersensitivity induced by inflammation or common 
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inflammatory mediators. A potential explanation is that mechanisms involved in changes in mechanical 
reflex withdrawal responses after peripheral nerve injury are dependent on centrally mediated effects, 
for instance downregulation of KCC2 function (Coull et al., 2003; Price and Prescott, 2015). This would 
suggest that different subsets of peripheral afferents are responsible for mechanical hypersensitivity 
under different injury conditions. In fact, mechanical hypersensitivity following nerve injury persists even 
when the vast majority of C-fibers are eliminated (Abrahamsen et al., 2008; Minett et al., 2014). On the 
other hand, eliminating neurons in the TRPM8 lineage is sufficient to eliminate cold hypersensitivity 
after peripheral nerve injury (Knowlton et al., 2013). We observed a strong decrease in cold 
hypersensitivity induced by nerve injury in eIF4ES209A and Mnk-/- mice and cercosporamide treatment 
was able to lead to a transient decrease in cold hypersensitivity. Therefore, our findings are consistent 
with the notion that MNK – eIF4E signaling is a key signaling hub for the sensitization of peripheral 
nociceptive neurons but that this signaling pathway is dispensable for the generation of mechanical 
hypersensitivity after nerve injury. In the nerve injury scenario this mechanical hypersensitivity could be 
generated exclusively via A-fiber input coupled to spinal dorsal horn disinhibitory mechanisms such 
as those observed after spinal BDNF (Lee and Prescott, 2015), cytokine (Kawasaki et al., 2008), 
chemokine (Gosselin et al., 2005) or PGE2 (Ahmadi et al., 2002) application or with traumatic injury to 
peripheral nerves (Coull et al., 2005; Abrahamsen et al., 2008; Minett et al., 2014). Another possibility 
is that different translation regulation mechanisms are involved in mechanical hypersensitivity after 
nerve injury. Interestingly, AMP activated protein kinase (AMPK) activators reduce neuropathic 
mechanical hypersensitivity in rats and mice (Melemedjian et al., 2010). AMPK activation inhibits both 
mTOR and MAPK pathway signaling (Melemedjian et al., 2010). Therefore, only influencing an end 
point of MAPK signaling in reduction of eIF4E phosphorylation may be insufficient to reduce neuropathic 
mechanical hypersensitivity and additional inhibition of mTOR signaling may be needed.  
Despite intact normal acute pain behavior and anatomy in eIF4ES209A mice we observed that 
DRG neurons surprisingly trended toward higher levels of excitability in response to slowly depolarizing 
ramp currents and a larger baseline sodium current density. On the other hand, these neurons fail to 
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demonstrate a change in excitability in response to either IL-6 or NGF in vitro, an effect that is reflected 
in a behavioral deficit in vivo. A very recent study revealed that eIF4E phosphorylation is mechanistically 
linked to stress granule formation and mRNA sequestration through an interaction with the eIF4E-
interacting protein 4E-T and that this leads to suppression of translation of some mRNAs (Martinez et 
al., 2015). While this has not been explored in neurons, it is possible that eIF4E phosphorylation can 
suppress translation of certain mRNA species under some circumstances and promote the translation 
of the same, or other, mRNAs in different circumstances, for instance in response to inflammatory 
mediators in DRG nociceptors. Such a mechanism linked to eIF4E phosphorylation could lead to the 
cellular phenotype of increased basal excitability but a loss of induced hyperexcitability in the complete 
absence of eIF4E phosphorylation. In fact, similar phenotypes have been consistently observed in Fmr1 
knockout mice (a model of fragile X syndrome) leading to baseline alterations in neuronal excitability 
or in signaling pathway efficacy coupled with a lack of plasticity (Grossman et al., 2006; Hanson and 
Madison, 2007; Pfeiffer and Huber, 2007; Bureau et al., 2008) including in the nociceptive system (Price 
et al., 2007). Interestingly, recent studies found that eIF4E phosphorylation is enhanced in fragile X 
syndrome and that crossing mice lacking fragile X mental retardation protein with eIF4ES209A mice or 
treating Fmr1 mutant mice with cercosporamide rescues many phenotypes in these mice (Gkogkas et 
al., 2014).  
An unanswered question arising from this work is what are the key mRNA targets for eIF4E 
phosphorylation in the context of nociceptor excitability. Our electrophysiology and Ca2+ imaging 
experiments provide some possible clues. The trafficking of channels to the membrane is an important 
regulatory mechanism for nociceptor excitability (Matsuoka et al., 2007; Hudmon et al., 2008; Andres 
et al., 2013). Our findings are consistent with a model where eIF4E phosphorylation enhances the 
translation of a subset of mRNAs that influence the membrane trafficking of voltage gated channels 
(e.g., VGNaCs, consistent with our current density experiments) and G-protein coupled receptors (e.g., 
PGE2 receptors, consistent with our Ca2+ imaging experiments) to enhance nociceptor excitability and 
increase their responsiveness to inflammatory mediators. While we cannot currently pinpoint the 
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identity of these locally translated mRNAs, we have now identified a precise signaling event that can 
be manipulated to identify these mRNAs. Discovering these eIF4E-controlled mRNAs will yield 
significant insight into how nociceptors alter their excitability downstream of initial phosphorylation 
events that are likely more transient than the synthesis of new proteins that contribute to the 
maintenance of long-term nociceptor plasticity. 
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FIGURE LEGENDS 
 
Figure 1. eIF4ES209A mice have normal acute nociceptive responses but decreased mechanical 
hypersensitivity to formalin and a group I mGluR agonist. A) eIF4ES209A and WT mice show no 
differences in tail-flick responses (55°C) (n ≥ 6) or B) baseline paw withdrawal thresholds (n ≥ 6). C, 
D) First phase (0–10 min) and second phase (15–45 min) summed responses were not different 
between eIF4ES209A and WT mice (n ≥ 10). E) Three days post intraplantar (i.pl.) 5 % formalin 
injection eIF4ES209A mice exhibited a significantly higher mechanical withdrawal threshold compared 
to WT mice (n ≥ 10). F, G) The mGlu1/5 receptor agonist, DHPG (50 nmol), was injected intrathecally 
(i.t.) in both WT and eIF4ES209A mice. Nocifensive behaviors summed during the 30 min after injection 
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were equal in both strains (n = 8). However, 6 hr post DHPG i.t. injection, WT mice exhibited 
mechanical hypersensitivity whereas eIF4ES209A mice did not (n = 8). **p<0.01; ****p<0.0001 
 
Figure 2. Normal development of nociceptive pathways in eIF4ES209A mouse DRG and spinal 
cord. A, B) WT and eIF4ES209A mouse spinal cords were immunostained with CGRP (cyan), TRPV1 
(green), and IB4 (red; representative images from n = 3 mice). C) Immunostaining for peripherin 
(green) and neurofilament 200 (NF200; red) in DRG from WT and eIF4ES209A mice show no 
differences in the proportion of peripherin positive neurons per section (n = 3), the proportion of 
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NF200-positive neurons per section (n = 3) or in overlap between the two markers (n = 3). D) WT and 
eIF4ES209A DRGs were stained for TRPV1 (red), IB4 (green), and CGRP (blue), and the proportion of 
neurons expressing each marker was assessed (TRPV1: WT mean = 34.3% ± 3.1% vs. eIF4ES209A 
mean = 32.9% ± 1.3%; IB4: WT mean = 19.6% ± 1.8% vs. eIF4ES209A mean = 17.8% ± 2.0%; WT 
mean = CGRP: 29.1% ± 1.5% vs. eIF4ES209A mean = 31.5% ± 2.0%). TRPV1 and IB4 populations 
were segregated in both mouse strains (TRPV1/IB4 overlap: WT mean = 3.7% ± 0.1% vs. eIF4ES209A 
mean = 3.2% ± 0.7%) while TRPV1 and CGRP overlapped substantially (TRPV1/CGRP overlap: WT 
mean = 74.2% ± 6.3% vs. eIF4ES209A mean = 71.1% ± 2.3%) as demonstrated in the proportional 
Venn diagrams. Scale bars represent 200 m. 
 
Figure 3. Normal ERK and 4E-BP phosphorylation in eIF4ES209A mouse DRG and spinal cord. 
A, B) eIF4ES209A DRG shows equal levels of ERK and 4E-BP phosphorylation while eIF4E 
phosphorylation is completely absent compared to WT DRG using western blot analysis (n ≥ 6). C, D) 
Additionally, spinal cord from eIF4ES209A shows similar levels of p-ERK and p-4E-BP compared to WT 
spinal cord (n ≥ 5). 
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Figure 4. Mechanical and thermal hypersensitivity, facial grimacing, and the development of 
hyperalgesic priming are decreased in eIF4ES209A mice. A) IL-6 (0.1 ng) was injected into the 
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hindpaw in both WT and eIF4ES209A mice. Hindpaw mechanical thresholds were measured at 3, 24, 
48, and 72 hr. eIF4ES209A mice exhibited reduced mechanical hypersensitivity compared to WT mice 
and (B) a deficit in hyperalgesic priming (n ≥ 6). C) eIF4ES209A mice also demonstrated decreased 
mechanical and (D, n = 6) thermal hypersensitivity in response to i.pl. injection of 50 ng NGF (n ≥ 6) 
and (E, F) NGF-induced hyperalgesic priming. G) I.pl. injection of 20 ng 2at-LIGRL likewise induced 
decreased mechanical hypersensitivity in eIF4ES209A mice and a decrease of hyperalgesic priming in 
response to IL-6 (H, n ≥ 6,), I) 2at-LIGRL induces facial grimacing in WT but not in eIF4ES209A mice, 
(J) moreover, eIF4ES209A mice fail to show facial grimacing after 2at-LIGRL priming when 
subsequently challenged with PGE2 (n ≥ 6). *p<0.05; **p<0.01; ***p<0.001 ****p<0.0001 
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Figure 5. MNK1/2 – eIF4E signaling contributes to the development of mechanical and thermal 
hypersensitivity and hyperalgesic priming in response to inflammatory stimuli. A, B) 
Carrageenan (0.5% w/v) was injected into the hindpaw in both WT and eIF4ES209A mice. Hindpaw 
mechanical and thermal thresholds show that eIF4ES209A mice exhibited a blunted mechanical and 
thermal hypersensitivity compared to WT mice (n ≥ 5). C) eIF4ES209A mice developed reduced 
hyperalgesic priming when injected with PGE2 (n  ≥ 5). D, E) Mnk1/2-/- mice injected i.pl. with CFA 
(0.5 mg/mL, 10μL) recover faster in both mechanical and thermal hypersensitivity compared to WT 
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mice (n = 9). F, G) Mnk1/2-/- mice show decreased mechanical and thermal response to PGE2 after 
recovering from the initial hypersensitivity from CFA (n = 9). *p<0.05; **p<0.01; ***p<0.001 
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Figure 6. Local inhibition of MNK1/2 with cercosporamide reduces eIF4E phosphorylation, 
mechanical hypersensitivity, grimacing, and inhibits the development of hyperalgesic priming. 
A) One hr in vitro treatment of DRG neurons with cercosporamide (cerco, 10 M) decreased eIF4E 
phosphorylation (n = 3) but did not influence 4E-BP1 phosphorylation (B, n = 3) or ERK 
phosphorylation (C, n = 3). D) Intraperitoneal injection of cercosporamide (40 mg/kg) results in a 
decreased eIF4E phosphorylation in DRGs (n = 3) but does not affect 4E-BP1 phosphorylation (E, n 
= 3). F, G) Mechanical hypersensitivity induced by NGF (50 ng) or 2at-LIGRL (20 ng) was reduced by 
cercosporamide (10 g, n ≥ 9). Similar to eIF4ES209A mice, pharmacological inhibition of MNK1/2 
using cercosporamide attenuated the development of hyperalgesic priming induced by NGF (H) and 
2at-LIGRL (I) (n ≥ 5).  J) Facial grimacing induced by i.pl. injection of 2at-LIGRL (20 ng) was also 
attenuated with local cercosporamide (10 g) treatment as was facial grimacing with subsequent 
PGE2 challenge (K, n ≥ 5). L) Immunostaining of glabrous skin for TRPV1 (red) and p-eIF4E (green) 
revealed that eIF4E phosphorylation is present in TRPV1-positive fibers in WT, but absent in 
eIF4ES209A mice. Scale bar represents 20 µm. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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Figure 7. MNK1/2 - eIF4E signaling mediates NGF- and IL-6- induced changes in excitability in 
DRG neurons. A) WT DRG neurons were exposed to NGF or vehicle 18-24 hr prior to patch clamp 
recordings. Ramp current-evoked spiking demonstrates that NGF exposure increases the excitability 
of WT DRG neurons. B) eIF4ES209A DRG neurons showed no difference in the number of spikes 
evoked by ramp currents between NGF and vehicle-treated DRG neurons. C) Membrane capacitance 
measures between WT and eIF4ES209A DRG neurons show no difference in neuron size between 
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samples demonstrating that small diameter neurons were used for recordings. D) Pharmacological 
inhibition of MNK1/2 using cercosporamide (10 M, n ≥ 9) recapitulated the effect seen in eIF4ES209A 
DRG neurons blocking NGF-induced hyperexcitability.  E) IL-6 (50 ng/ml) exposure to WT DRG 
neurons for 1 hr caused an increase in excitability compared to vehicle but failed to do so in 
eIF4ES209A DRG neurons (F). G) Membrane capacitance between these samples was not different. N 
for each condition is shown in the appropriate bar. H) Cercosporamide blocked enhanced excitability 
induced by IL-6 in small diameter DRG neurons (50ng/mL) (n ≥ 7). Traces shown in all panels are for 
the 700 pA stimulus. *p<0.05; **p<0.01; ***p<0.001 
 
Figure 8. Cercosporamide has no additional effect in eIF4ES209A mice and no acute effect on 
sodium current density. A) Mechanical hypersensitivity induced by NGF (50 ng) showed no 
difference between eIF4ES209A mice that additionally received a hindpaw injection of cercosporamide 
(10 μg) and eIF4ES209A mice that did not (n ≥ 4, p > 0.05, two-way ANOVA). B) Subsequent injection 
of PGE2 to precipitate priming also shows no difference between eIF4ES209A mice that previously 
received cercosporamide and eIF4ES209A mice that did not (n ≥ 4, p > 0.05, two-way ANOVA). Sodium 
current (C) and sodium current density (D) were measured in WT DRG neurons with cercosporamide 
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(10 μM) perfused acutely over a 5-10 sec period (n = 4, p > 0.05, two-way ANOVA) indicating the 
cercosporamide does not block voltage-gated sodium channels at this concentration. 
 
Figure 9.  IL6-induced sustained spiking and increased voltage gated sodium current density 
is altered in eIF4ES209A DRG neurons. A) Image of DRG neurons cultured on an MEA device. Scale 
bar represents 200m. B) Raster plot showing electrical activity of WT and eIF4ES209A DRG neuronal 
networks observed using MEAs during BL, IL-6 treatment, and 1 hr wash. C) IL-6 elicited increased 
spiking in WT DRG cultures during treatment that was sustained throughout the washout period and 
significantly greater than spiking observed in eIF4ES209A DRG neurons. D, E) Sodium current density 
was increased after 1 hr after IL-6 exposure in WT DRG neurons, but was decreased in eIF4ES209A 
DRG neurons (WT: n ≥ 7, eIF4ES209A: n ≥ 12). *p<0.05, ***p<0.001 
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Figure 10. IL-6 treatment alters PGE2 responsiveness in DRG neurons in an eIF4E 
phosphorylation-dependent fashion. WT and eIF4ES209A DRG neurons were cultured and treated 
with VEH or IL-6 (50 ng/mL) for 1 hr. PGE2 (1 nM) was perfused for 30 sec during which Ca2+ 
responses were measured (A & B). C) IL-6 treatment decreased the latency of PGE2-evoked Ca2+ 
release in WT DRG neurons compared to vehicle-treated WT neurons (n ≥ 50). D) The proportion of 
neurons responding to PGE2 was increased after IL-6 exposure in WT DRG neurons but was 
unchanged in eIF4ES209A DRG neurons. Scale bar represents 20 µm. ****p<0.0001  
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Figure 11. Normal Ca2+ signaling evoked by KCl and capsaicin in eIF4ES209A DRG neurons. A) 
WT and eIF4ES209A DRG neurons were imaged after 1 hr vehicle or IL-6 (50 ng) treatment during 
vehicle-containing bath solution and capsaicin (250 nM)-containing bath solution perfusions. B) The 
proportion of TRPV1-positive neurons were unchanged in WT and eIF4ES209A DRG neurons treated 
with vehicle of IL-6. C) Moreover, Ca2+ signaling evoked by KCl (50 mM) was unchanged in all 
conditions (n ≥ 57 neurons per condition, p>0.05, one-way ANOVA). Scale bar represents 20 µm. 
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Figure 12. Decreased neuropathic pain in eIF4ES209A mice and through MNK1/2 inhibition. A) 
Following SNI surgery eIF4ES209A mice show reduced mechanical hypersensitivity that normalizes 14 
days following surgery compared to WT mice (n = 8). B) Mnk1/2-/- mice show blunted mechanical 
hypersensitivity lasting 35 days post SNI surgery (n = 10). C) Following SNI eIF4ES209A mice have a 
decrease in cold hypersensitivity as measured in the acetone test compared to WT mice (n = 8). D) 
Mnk1/2-/- mice show a sustained decrease in cold hypersensitivity after SNI compared to WT mice (n 
= 10). E) Following systemic administration of cercosporamide (40 mg/kg) for 3 days, WT mice show 
a transient decrease in cold hypersensitivity (n = 4). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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TABLES 
Table 1: List of antibodies used in this study. 
Primary antibodies Catalog number Incubation Secondary antibodies 
eIF4E phospho- 9741S 
phospho (IHC)- ab76256 
total- 9742S 
p- 1:500; p(IHC)- 
1:1000; t- 1:1000; 
overnight @ 4 °C 
Goat anti-rabbit (WB:1:10,000; 
IHC:1:1,000); 1 hr @ RT 
4EBP1 phospho- 9459S 
total- 9452S 
p- 1:500; t- 1:1000; 
overnight @ 4 °C 
Goat anti-rabbit (1:10,000); 1 hr 
@ RT 
ERK phospho- 9101S 
total- 9102S 
p- 1:3,000; t- 
1:3,000; overnight 
@ 4 °C 
Goat anti-rabbit (1:10,000); 1 hr 
@ RT 
GAPDH 2118 1:10,000; overnight 
@ 4 °C 
Goat anti-rabbit (1:10,000); 1 hr 
@ RT 
Peripherin SAB 4502419 1:500; overnight @ 
4 °C 
Alexa-fluor goat anti-rabbit 488 
(1:1,000); 1 hr @ RT 
Neurofilament 200 N0142 1:400; overnight @ 
4 °C 
Alexa-fluor goat anti-mouse 
568 (1:1,000); 1 hr @ RT 
Isolectin B4- 568 I21412 Spinal cord- 1:1000; 
DRG- 1:400; 
overnight @ 4 °C 
none 
CGRP T-4032 Spinal cord & DRG- 
1:1000; overnight @ 
4 °C 
Alexa-fluor goat anti-rabbit 647 
(1:2,000); 1 hr @ RT 
TRPV1 GP14100 Spinal cord & DRG- 
1:1000; Skin-
1:3,000; overnight 
@ 4 °C 
Alexa-fluor goat anti-guinea pig 
488 (1:2,000); 1 hr @ RT 
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Table 2: Sex of animals by genotype in behavioral experiments in this study. 
Test WT Males WT Females eIF4ES209A Males eIF4ES209A 
Females 
Tail Flick/ von Frey 4 4 7 5 
Formalin 6 4 7 5 
DHPG 5 3 4 4 
IL-6 5 3 6 4 
NGF 4 4 4 2 
NGF thermal - 6 - 6 
2at-LIGRL (PAR2) 4 2 4 2 
Grimace [2at-LIGRL 
(PAR2)] 
4 1 - 6 
Carrageenan 5 - 6 - 
Carrageenan thermal 5 - 5 - 
CFA (MNK-/-) 4 5 4 (MNK-/-) 5 (MNK-/-) 
Cercosporamide + 
NGF (in eIF4ES209A 
mice) 
- - 4 7 
SNI 4 4 6 2 
SNI (in MNK-/- mice) 10 - 10 (MNK-/-) - 
Cercosporamide 
(SNI) 
4 4 - - 
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Table 3: Different translation regulation pathways control different aspects of pain and pain 
amplification 
Mutant mouse Thermal Mechanical Thermal 
hyperalgesia 
Mechanical 
hyperalgesia 
Proposed 
mechanism 
eIF4ES209A Normal Normal Decreased to 
inflammatory 
stimuli 
Decreased to 
inflammatory 
stimuli 
Decreased 
nociceptor 
plasticity 
MNK-/- Normal Normal Decreased to 
inflammatory 
stimuli 
Decreased to 
inflammatory 
stimuli and 
neuropathic 
Decreased 
nociceptor 
plasticity 
Eif4ebp1-/- (Khoutorsky 
et al., 2015) 
 
Normal Increased 
sensitivity 
Not tested Increased 
hypersensitivity 
to inflammatory 
stimuli 
Decreased 
spinal 
neuroligin 1 
eIF2+/S51A(Khoutorsky 
et al., 2016) 
Decreased 
sensitivity 
Normal Not tested Decreased 
hypersensitivity 
to inflammatory 
stimuli 
Decreased 
TRPV1 
functional 
activity in 
DRG 
Fmr1 KO (Price et al., 
2007) 
Normal Normal Not tested Decreased 
hypersensitivity 
to inflammatory 
and 
neuropathic 
stimuli 
Decreased 
spinal and 
peripheral 
mGluR1/5 & 
mTOR 
signaling 
 
